Cite
HARVARD Citation
Bischoff, J. et al. (2019). A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA). Anti-cancer drugs. 30 (4), p. . [Online].